CA2383076A1 - Facteurs stimulant la survie de neurones dopaminergiques et leur utilisation - Google Patents

Facteurs stimulant la survie de neurones dopaminergiques et leur utilisation Download PDF

Info

Publication number
CA2383076A1
CA2383076A1 CA002383076A CA2383076A CA2383076A1 CA 2383076 A1 CA2383076 A1 CA 2383076A1 CA 002383076 A CA002383076 A CA 002383076A CA 2383076 A CA2383076 A CA 2383076A CA 2383076 A1 CA2383076 A1 CA 2383076A1
Authority
CA
Canada
Prior art keywords
arginine
rich protein
cells
compound
survival
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002383076A
Other languages
English (en)
Inventor
John Commissiong
Andrei A. Raibekas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROTROPHIC BIOSCIENCE Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2383076A1 publication Critical patent/CA2383076A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention a trait à une composition pharmaceutique contenant une protéine riche en arginine ainsi qu'un excipient acceptable du point de vue pharmaceutique. Elle concerne également des méthodes de traitement de maladies neurodégénératives, des techniques permettant de renforcer la survie de neurones lors de transplantation cellulaire ou à la suite de celle-ci, des procédés de production de neurones aux fins de transplantation ainsi que des techniques permettant d'identifier des composés modulant ou mimant l'activité biologique d'une protéine riche en arginine.
CA002383076A 1999-09-16 2000-09-18 Facteurs stimulant la survie de neurones dopaminergiques et leur utilisation Abandoned CA2383076A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15466899P 1999-09-16 1999-09-16
US60/154,668 1999-09-16
PCT/CA2000/001049 WO2001019851A2 (fr) 1999-09-16 2000-09-18 Facteurs stimulant la survie de neurones dopaminergiques et leur utilisation

Publications (1)

Publication Number Publication Date
CA2383076A1 true CA2383076A1 (fr) 2001-03-22

Family

ID=22552259

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002383076A Abandoned CA2383076A1 (fr) 1999-09-16 2000-09-18 Facteurs stimulant la survie de neurones dopaminergiques et leur utilisation

Country Status (6)

Country Link
EP (1) EP1220681A2 (fr)
JP (1) JP2003511352A (fr)
AU (1) AU7263300A (fr)
CA (1) CA2383076A1 (fr)
MX (1) MXPA02002765A (fr)
WO (1) WO2001019851A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5091201A (en) * 2000-03-21 2001-10-03 Curagen Corp Vegf-modulated genes and methods employing them
EP1373502B8 (fr) 2001-03-20 2010-12-22 Amarantus Therapeutics, Inc. Facteurs promoteurs de la survie des neurones dopaminergiques et utilisations associees
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
EP1644406B1 (fr) 2003-07-11 2012-08-15 DeveloGen Aktiengesellschaft Utilisation de produits des proteines dg153 secretees pour la prevention et le traitement de maladies du pancreas et/ou de l'obesite et/ou du syndrome metabolique
DE602005023550D1 (de) 2005-12-14 2010-10-21 Licentia Ltd Verwendungen eines neurotrophischen Faktors
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
GB0908934D0 (en) * 2009-05-26 2009-07-01 Univ The West Of Scotland Differentiation medium
WO2015149005A1 (fr) * 2014-03-28 2015-10-01 Buck Institute For Research On Aging Méthodes et compositions pour moduler le système immunitaire

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219839B (it) * 1988-02-08 1990-05-24 Fidia Farmaceutici Purificazione,caratterizazione e applicazione di un fattore neuronotrofico derivato da cervello di nammifero
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
DE69334344D1 (de) * 1992-10-28 2010-11-18 Neurospheres Holding Ltd Biologische Faktoren und neuronale Stammzellen
WO1996033731A1 (fr) * 1995-04-26 1996-10-31 Regeneron Pharmaceuticals, Inc. Procedes d'utilisation des facteurs neurotrophiques pour faciliter les greffes de neurones
US6222022B1 (en) * 1996-03-14 2001-04-24 Washington University Persephin and related growth factors

Also Published As

Publication number Publication date
WO2001019851A2 (fr) 2001-03-22
EP1220681A2 (fr) 2002-07-10
JP2003511352A (ja) 2003-03-25
MXPA02002765A (es) 2005-09-08
WO2001019851A3 (fr) 2001-09-20
AU7263300A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
US20170298110A1 (en) Dopaminergic neuronal survival-promoting factors and uses thereof
US7563862B2 (en) Neural regeneration peptides and methods for their use in treatment of brain damage
US20190060402A1 (en) Method of enhancing dopaminergic neuronal cell growth or survival with manf
JP5241037B2 (ja) 截形グリア細胞系由来神経栄養因子
Timmer et al. Enhanced survival, reinnervation, and functional recovery of intrastriatal dopamine grafts co-transplanted with Schwann cells overexpressing high molecular weight FGF-2 isoforms
AU707599B2 (en) Use of neuregulins as modulators of cellular communication
JPH10504705A (ja) 色素上皮誘導因子：ｐｅｄｆ遺伝子の特性評価、ゲノム構成および配列
Cunningham et al. Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease
CA2383076A1 (fr) Facteurs stimulant la survie de neurones dopaminergiques et leur utilisation
JP4399260B2 (ja) 神経再生ペプチドおよび脳損傷治療におけるその使用方法
Bauer et al. Nonviral glial cell-derived neurotrophic factor gene transfer enhances survival of cultured dopaminergic neurons and improves their function after transplantation in a rat model of Parkinson’s disease
AU2002240760A1 (en) Dopaminergic neuronal survival-promoting factors and uses thereof
Krieglstein et al. Protein from chromaffin granules promotes survival of mesencephalic dopaminergic neurons by an EGF‐receptor ligand‐mediated mechanism
US20030113869A1 (en) Human FGF gene and gene expression products
WO1994013800A2 (fr) Preparation a base de proteine mk et son utilisation dans les cultures cellulaires

Legal Events

Date Code Title Description
FZDC Correction of dead application (reinstatement)
FZDE Dead